NCT02487225 - Pentoxifylline Treatment in Acute Pancreatitis (AP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

October 31, 2017

Conditions

Acute Pancreatitis (AP)Gallstone PancreatitisAlcoholic PancreatitisTrauma Acute PancreatitisHypertriglyceridemia Acute PancreatitisIdiopathic (Unknown) Acute PancreatitisMedication Induced Acute PancreatitisCancer Acute PancreatitisMiscellaneous (i.e. Acute on Chronic Pancreatitis)

Interventions

DRUG

Pentoxifylline

Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors

DRUG

Placebo

A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester